



innate pharma

innate
pharma

2018
HIGHLIGHTS



OUR MISSION

Transform the lives of people with cancer, with innovative immunology drugs based on our scientific expertise in immunology.

BECOME A LEADER IN IMMUNO-ONCOLOGY

Create value for stakeholders: patients, employees, shareholders, industry and academic partners, local ecosystem.

<p>Strengthen our diverse portfolio of first or best-in-class drug candidates</p>	<p>Establish the Company as a preferred partner for leading immunology companies</p>	<p>Moving towards an integrated biopharmaceutical company</p>
<ul style="list-style-type: none"> • Building on Innate Pharma's expertise in immunology to enlarge the Company's operations in immunology • Bringing new and innovative therapeutic options to patients 	<ul style="list-style-type: none"> • Maximizing the potential of our products and accelerating their development • Strengthening our competencies while optimizing resource allocation 	<ul style="list-style-type: none"> • Retaining more value in-house • Gradually integrating the downstream steps of the value chain: adding expertise in late-stage clinical development and preparing the organization for commercialization

14 MILLION
NEW CASES
EVERY YEAR

8 MILLION
DEATHS EVERY YEAR

**CANCER,
A PUBLIC
HEALTH ISSUE**

IMMUNOTHERAPY IS AT THE FOREFRONT OF CANCER RESEARCH

26

APPROVED
IMMUNOTHERAPIES
IN ONCOLOGY INCLUDING

INCLUDING

6

ANTIBODIES
TARGETING IMMUNE
CHECKPOINTS

60%

OF THE ONCOLOGY
MARKET IN 2025*

*Source: The immuno-oncology race: myths and emerging realities - Stephen Cavnar, Pedro Valencia, Jesse Brock, Judith Wallenstein and Valery Panier - Nature Review Drug Discovery, Vol 16, Feb 2017, 83-84



MONDHER MAHJOUBI
Chief Executive Officer and Chairman of the Executive Board

"We have built a portfolio of product candidates with innovative and complementary mechanisms of action. Several are at a clinical stage and we are expecting major short and mid-term catalysts. Our ambition is to become a leader in the field of cancer immunotherapy by building on our scientific expertise, our teams' commitment and the quality of our partnerships."




DEVELOPING A NEW GENERATION OF TREATMENTS


Immuno-oncology is a new immunotherapy approach aiming to re-establish the immune system's ability to recognize and eliminate tumor cells.

Scientific expertise based on three pillars

Innate Pharma has built its scientific expertise on the understanding of the innate immune system. Based on this knowledge, Innate Pharma has expanded its field of research by integrating two other parts of the immune response: targeting tumor antigens and the tumor microenvironment.



IMMUNE CHECKPOINTS
Re-establish immune effector cell function to eliminate tumor cells



TUMOR ANTIGENS
Targeting specific antigens on tumor cells and subsequent elimination by immune effector cells



TUMOR MICROENVIRONMENT
Restoring immune effector cell function by reversing immunosuppression



ÉRIC VIVIER
Chief Scientific Officer

“Immunotherapy is radically changing cancer treatment and is being enthusiastically embraced by doctors and scientists. Innate Pharma has, since its inception, had unique understanding of this field and has developed a differentiated approach. We have developed a strong expertise in the understanding of the immune system’s mechanisms and pathways to engage it against tumor cells. We are striving to develop a new generation of drugs in immunotherapy that comes with higher efficacy and will benefit to more patients.”

A balanced and diversified portfolio in immuno-oncology

	PRECLINICAL	DOSE FINDING	SIGNAL DETECTION	PIVOTAL
IMMUNE CHECKPOINTS	Anti-SIGLEC-9		Monalizumab Anti-NKG2A	
TUMOR ANTIGENS	IPH4301 Anti-MICA		IPH4102 Anti-KIR3DL2	
TUMOR MICROENVIRONMENT	IPH52 Anti-CD39	IPH5401 Anti-C5AR	IPH53 Anti-CD73	

Monalizumab is partnered with AstraZeneca/MedImmune through a co-development and commercialization agreement. Liriluma (anti-KIR2DL-1,-2,-3), under review, is licensed to Bristol-Myers Squibb.

CLINICAL ADVANCES 2017/2018

June & October 2017

Dose-escalation results for IPH4102: favorable safety profile and promising clinical activity (Meeting of Lugano and EORTC CLTF)

June 2017

Acquisition of the anti-C5aR clinical program (IPH5401) from Novo Nordisk A/S

July 2017

Start of cohort expansion in the IPH4102's Phase I study

November 2017

Update on the lirilumab program

January 2018

New clinical collaboration with AstraZeneca/MedImmune for IPH5401

March 2018

Expansion of the clinical trial evaluating monalizumab in combination with durvalumab in solid tumors to include new cohorts of colorectal cancer patients

April 2018

Preliminary data suggest promising anti-tumor activity of monalizumab in combination with cetuximab in patients with platinum pretreated head and neck cancer

June 2018

Preliminary data from the study of monalizumab in combination with durvalumab show anti-tumor activity in colorectal cancer patients

2nd half of 2018*

- Start of Stellar-001, a trial evaluating IPH5401 in combination with durvalumab in selected solid tumors
- First patient in new trial evaluating monalizumab in combination with durvalumab in head and neck cancer
- Cohort expansion data of the Phase I trial evaluating IPH4102 in cutaneous T cell lymphomas

* expected upcoming events



PIERRE DODION
Chief Medical Officer

“Even today, a substantial medical need remains in patients with several types of cancer. Irrespective of the considerable progresses we have seen, there is still a need for new and effective treatments that are well tolerated and appropriate for individual

patients, especially for patients with advanced cancers. Initial clinical data for our product candidates have demonstrated that they could address this need, notably in combination with other drugs. 2018 is an important year for Innate Pharma with clinical data read-outs for our most advanced product candidates, monalizumab and IPH4102.”

ACCELERATE PORTFOLIO DEVELOPMENT

Over the years, Innate Pharma's strong scientific expertise has enabled the Company to partner with leading biopharmaceutical companies:



Innate Pharma also relies on a network of academic and clinical centers as well as on the local ecosystem expert in immunology.



YANNIS MOREL
Product portfolio strategy & Business development, member of the Executive Board

“Scientific and industrial collaborations have always been important to Innate Pharma’s development model. Historically, we have always had an ability to sign high-quality agreements

with leading pharmaceutical players, and have benefited from financial resources and expertise that have supported our programs. As our portfolio matures, we are focusing more on collaborations with the objective of maximizing the value for our products and retaining more of this value in-house.”


CONTINUED GROWTH

To support its long term development, both from a medical and talent perspective, Innate Pharma recruits highly-qualified multidisciplinary teams.



Data as of Dec 31, 2017

HEADCOUNT PROGRESS




MAIN SHAREHOLDERS

€330 M MARKET CAP.

€154 M OF CASH

Data as of March 31, 2018



ODILE LAURENT

Human Resources Director

“Innate Pharma is expanding and has ambitious goals. Our workforce is growing, and we are constantly integrating new skills and new activities while supporting our managers in the development of their teams. In order to sustain our high level of innovation in the very competitive and complex field of immuno-oncology, we have to adapt our organization while maintaining and leveraging the collective intelligence which makes Innate Pharma successful.”

“INNATE IN ACTIONS” THE SHAREHOLDER’S CLUB

900
MEMBERS

1 MONTHLY
NEWSLETTER

DEDICATED
MEETINGS

As a member of the club “Innate en Actions”, you will benefit from:

- Detailed, up-to-date information on Innate Pharma and its fields of operations by receiving our press releases as well as the monthly newsletter. Dedicated to the members of the club, the letter “Innate en Actions” offers an overview of Innate Pharma’s news as well as comments on the stock market.

- Invitations for medical conferences, site tours and meetings with the management team



Subscribe via our website or flash the code with your smartphone (the “Innate en Actions” letter is available in French only).



CONTACTS

business@innate-pharma.fr
corporate@innate-pharma.fr
investors@innate-pharma.fr
jobs@innate-pharma.fr
medical@innate-pharma.fr
press@innate-pharma.fr
science@innate-pharma.fr



innate pharma

SOCIÉTÉ ANONYME ORGANIZED WITH AN EXECUTIVE BOARD AND A SUPERVISORY BOARD

Registered Office: 117 avenue de Luminy - 13276 MARSEILLE CEDEX 9 - FRANCE
Tél. +33 (0)4 30 30 30 30 - Fax +33 (0)4 30 30 30 00 - Mail: info@innate-pharma.fr

innate-pharma.com